These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8424911)

  • 1. A phase II study of epirubicin in advanced transitional cell bladder cancer. The Yorkshire Urological Cancer Research Group.
    Jones WG; Sokal MP; Ostrowski MJ; Newling DW
    Clin Oncol (R Coll Radiol); 1993; 5(1):25-9. PubMed ID: 8424911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-centre phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer. Yorkshire and Scottish Urological Cancer Research Groups.
    Whelan P; Cumming JA; Garvie WH; Hargreave TB; Kirk D; Newling DW; Robinson MR; Smith PH
    Br J Urol; 1991 Jun; 67(6):600-2. PubMed ID: 2070204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose intermittent 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in poor risk patients with advanced transitional cell bladder cancer: a pilot study.
    Lelli G; Tononi A; Bacchetti P; Maver P; Corrado G; Garofalo F; De Santis P; Pannuti F
    J Chemother; 1989 Aug; 1(4):269-71. PubMed ID: 2809695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
    J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
    Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
    Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
    Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.
    Okamura K; Murase T; Obata K; Ohshima S; Ono Y; Sakata T; Hasegawa Y; Shimoji T; Miyake K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S31-5. PubMed ID: 7994783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin: a phase II study in recurrent small-cell lung cancer.
    Rosenthal M; Kefford R; Raghavan D; Stuart-Harris R
    Cancer Chemother Pharmacol; 1991; 28(3):220-2. PubMed ID: 1713130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group.
    Bono AV; Hall RR; Denis L; Lovisolo JA; Sylvester R
    Eur Urol; 1996; 29(4):385-90. PubMed ID: 8791042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. EORTC-GU Group protocol 30867.
    Fosså SD; Splinter T; Roozendaal KJ; Veenhof KH; Pavone-Macaluso M; Calciati A; de Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):389-90. PubMed ID: 2702991
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study.
    Skarlos DV; Aravantinos G; Linardou E; Kostakopoulos CA; Kastriotis I; Christodoulou C; Picramenos D; Giannakakis T; Dimopoulos K; Fountzilas G
    Eur Urol; 1997; 31(4):420-7. PubMed ID: 9187901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
    Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group.
    Watanabe N; Miyagawa I; Higasibori Y; Nakahara T; Sumi F; Ishida G; Abe B; Inoue A; Hanamoto N
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S57-9. PubMed ID: 7994788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.
    Maru A; Akaza H; Isaka S; Koiso K; Kotake T; Machida T; Matsumura Y; Nakagami Y; Niijima T; Obata K
    Cancer Chemother Pharmacol; 1987; 20 Suppl():S44-8. PubMed ID: 3311445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed high-dose intravesical epirubicin therapy of superficial bladder cancer. A way to reduce the side effects and increase the efficacy--a phase 2 trial.
    Bassi P; Spinadin R; Longo F; Saraeb S; Pappagallo GL; Zattoni F; Pagano F
    Urol Int; 2002; 68(4):216-9. PubMed ID: 12053020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cooperative phase II study of epirubicin (EPI) in bladder cancer, renal pelvic and ureteral tumors--Urological Cooperative Study Group of EPI].
    Niijima T; Koyanagi T; Maru A; Sakashita S; Koiso K; Ishikawa H; Uchida K; Shimazaki J; Isaka S; Akaza H
    Hinyokika Kiyo; 1986 Sep; 32(9):1359-69. PubMed ID: 3468792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group.
    Quoix EA; Giaccone G; Jassem J; Karnicka H; Wiatr E; Cortes-Funes H; Roozendaal KJ; Kirkpatrick A; Evrard D; van Zandwijk N
    Eur J Cancer; 1992; 28A(10):1667-70. PubMed ID: 1327019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour.
    Cumming JA; Kirk D; Newling DW; Hargreave TB; Whelan P
    Eur Urol; 1990; 17(1):20-2. PubMed ID: 2180719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
    Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
    Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin).
    Lorusso V; Pagliarulo A; Selvaggi FP; Durini E; Riccardi F; Comella P; Fiorillo C; De Lena M
    J Chemother; 1996 Apr; 8(2):154-8. PubMed ID: 8708748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.